Stirrup OT, et al. - Researchers sought to evaluate the long-term rates of virological failure and treatment interruption for people living with HIV (PLWHIV) with viral suppression on first-line efavirenz + tenofovir disoproxil fumarate + emtricitabine/lamivudine (EFV + TDF + FTC/3TC). In addition, they compared these according to patient characteristics. From the Collaboration of Observational HIV Epidemiological Research Europe cohort collaboration, they identified 19,527 eligible PLWHIV with median (interquartile range) follow-up 3.7 (2.0–5.6) years after initial viral suppression. The estimated rate of the combined incidence of virological failure or treatment interruption fell from 9.0/100 person-years in the first year to less than 4/100 person-years beyond 3 years from suppression. On considering only those remaining on EFV + TDF + FTC/3TC, they noted a reduction in the combined rate from 8.2/100 person-years in the first year to less than 3.5/100 person-years beyond 3 years. These findings suggest low rates of virological failure and treatment interruption up to 10 years from initial suppression among PLWHIV starting first-line EFV + TDF + FTC/3TC. Subpopulations with higher risks of these outcomes could be identified using demographic characteristics.